Boston Scientific Corp (BSX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Boston Scientific Corp stock (BSX) is currently trading at $69.78. Boston Scientific Corp PE ratio is 35.13. Boston Scientific Corp PS ratio (Price-to-Sales) is 5.05. Analyst consensus price target for BSX is $102.00. WallStSmart rates BSX as Hold.
Boston Scientific Corp (BSX) stock price prediction for 2030: Base case $55.54. Bull case $69.43. Bear case $41.66. See full BSX 2030 price forecast and methodology on WallStSmart.
- BSX PE ratio analysis and historical PE chart
- BSX PS ratio (Price-to-Sales) history and trend
- BSX intrinsic value — DCF, Graham Number, EPV models
- BSX stock price prediction 2025 2026 2027 2028 2029 2030
- BSX fair value vs current price
- BSX insider transactions and insider buying
- Is BSX undervalued or overvalued?
- Boston Scientific Corp financial analysis — revenue, earnings, cash flow
- BSX Piotroski F-Score and Altman Z-Score
- BSX analyst price target and Smart Rating
Boston Scientific Corp
📊 No data available
Try selecting a different time range
BSX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Boston Scientific Corp (BSX)
BSX is trading near its Graham intrinsic value of $70.62, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Boston Scientific Corp (BSX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, institutional own.. Fundamentals are solid but monitor weak areas for improvement.
Boston Scientific Corp (BSX) Key Strengths (3)
Growing significantly faster than its price suggests
95.05% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Boston Scientific Corp (BSX) Areas to Watch (7)
Premium valuation at 5.0x annual revenue
Premium pricing at 4.3x book value
Moderate profitability with room for improvement
Decent operational efficiency, solid but not exceptional
Solid revenue growth at 15.90% per year
Solid earnings growth at 18.50%
Decent profitability, keeps $14 per $100 revenue
Supporting Valuation Data
Boston Scientific Corp (BSX) Detailed Analysis Report
Overall Assessment
This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.7/10) while 7 fall into concern territory (avg 5.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.75) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Return on Equity. Some valuation metrics including Price/Sales (5.05), Price/Book (4.25) suggest expensive pricing. Growth concerns include Revenue Growth at 15.90%, EPS Growth at 18.50%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.40%, Operating Margin at 19.70%, Profit Margin at 14.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 15.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Institutional Own.) and negatives (Price/Sales, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BSX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BSX's Price-to-Sales ratio of 5.05x trades 88% above its historical average of 2.68x (94th percentile), historically expensive. The current valuation is 11% below its historical high of 5.67x set in Sep 2018, and 410% above its historical low of 0.99x in Oct 2012.
WallStSmart Analysis Synopsis
Data-driven financial summary for Boston Scientific Corp (BSX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Boston Scientific Corp is a strong growth company balancing expansion with improving profitability. Revenue reached 20.1B with 16% growth year-over-year. Profit margins of 14.4% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 1.0B in free cash flow and 1.4B in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Boston Scientific Corp push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Boston Scientific Corp.
Bottom Line
Boston Scientific Corp offers an attractive blend of growth (16% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Boston Scientific Corp(BSX)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.